Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-05-17 | Ms. Linda S. Palczuk, age 56, is the Chief Operating Officer of Verrica Pharmaceuticals, Inc.... It is anticipated that, upon election to our Board, Ms. Palczuk will join the Compensation Committee as its Chairman and the Audit and Nominating and Corporate Governance Committees as a member. She received no compensation from the Company during 2017. |
| 2019-04-30 | Ms. Linda S. Palczuk, age 57, has been a member of the Board of Directors since July 2018... Ms. Palczuk brings to the Board and the Compensation and Nominating and Corporate Governance Committees over 34 years of experience. |
| 2020-04-27 | Linda S. Palczuk, 58, has been a member of the Board of Directors since July 2018. Since September 2019, Ms. Palczuk has been the Chief Operating Officer and a director of Envara Health, Inc., a medical nutrition technology company. Ms. Palczuk was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, from February 2018 to April 2019. |
| 2021-04-30 | Linda S. Palczuk, 59, Director, Committees: (3*)(4), Compensation: $297,226 |
| 2022-04-29 | Linda S. Palczuk, 60, has been a member of the Board since July 2018. Since September 2019, Ms. Palczuk has been the Chief Operating Officer and a director of Envara Health, Inc., a medical nutrition technology company. Ms. Palczuk was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, from February 2018 to April 2019. |
| 2023-04-28 | Linda S. Palczuk, 61, has been a member of the Board since July 2018. From September 2019 to December 2022, Ms. Palczuk served as the Chief Operating Officer and a director of Envara Health, Inc., a medical nutrition technology company. Before that, Ms. Palczuk was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, from February 2018 to April 2019. Prior to joining Verrica Pharmaceuticals, from July 2017 to February 2018, Ms. Palczuk was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Prior to her position at Osiris Therapeutics, Ms. Palczuk had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general management roles, including Vice President, Established Brands and Vice President, Global Commercial Excellence from January 2012 until March 2015, Vice President, Sales & Marketing from March 2009 to December 2011, and Vice President, Sales from April 2006 to February 2009. |
| 2024-06-18 | Linda S. Palczuk, 62, has been a member of the Board since July 2018. The Board has a Compensation Committee composed of Linda S. Palczuk (Chair), Dr. Mark A. McCamish and Peter J. Thornton. The Board has a Nominating and Corporate Governance Committee, composed of Dr. Eric J. Ende (Chair), Geoffrey M. Glass and Linda S. Palczuk. |
Data sourced from SEC filings. Last updated: 2026-02-08